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Abstract
Background: Imatinib-resistant chronic myeloid leukemia (CML) patients receiving second-line tyrosine kinase
inhibitor (TKI) therapy with dasatinib or nilotinib have a higher risk of disease relapse and progression and not
infrequently BCR-ABL1 kinase domain (KD) mutations are implicated in therapeutic failure. In this setting, earlier
detection of emerging BCR-ABL1 KD mutations would offer greater chances of efficacy for subsequent salvage
therapy and limit the biological consequences of full BCR-ABL1 kinase reactivation. Taking advantage of an already
set up and validated next-generation deep amplicon sequencing (DS) assay, we aimed to assess whether DS may
allow a larger window of detection of emerging BCR-ABL1 KD mutants predicting for an impending relapse.
Methods: a total of 125 longitudinal samples from 51 CML patients who had acquired dasatinib- or nilotinib-
resistant mutations during second-line therapy were analyzed by DS from the time of failure and mutation
detection by conventional sequencing backwards. BCR-ABL1/ABL1%IS transcript levels were used to define whether
the patient had ‘optimal response’, ‘warning’ or ‘failure’ at the time of first mutation detection by DS.
Results: DS was able to backtrack dasatinib- or nilotinib-resistant mutations to the previous sample(s) in 23/51
(45 %) pts. Median mutation burden at the time of first detection by DS was 5.5 % (range, 1.5–17.5 %); median
interval between detection by DS and detection by conventional sequencing was 3 months (range, 1–9 months). In
5 cases, the mutations were detectable at baseline. In the remaining cases, response level at the time mutations
were first detected by DS could be defined as ‘Warning’ (according to the 2013 ELN definitions of response to
2nd-line therapy) in 13 cases, as ‘Optimal response’ in one case, as ‘Failure’ in 4 cases. No dasatinib- or nilotinib-
resistant mutations were detected by DS in 15 randomly selected patients with ‘warning’ at various timepoints, that
later turned into optimal responders with no treatment changes.
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Conclusions: DS enables a larger window of detection of emerging BCR-ABL1 KD mutations predicting for an
impending relapse. A ‘Warning’ response may represent a rational trigger, besides ‘Failure’, for DS-based mutation
screening in CML patients undergoing second-line TKI therapy.
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Background
Several tyrosine kinase inhibitors (TKIs) can effectively
target the BCR-ABL1 oncoprotein resulting from the
t(9;22) chromosomal translocation in chronic myeloid
leukemia (CML) patients. However, resistance continues
to be a significant challenge in the management of CML.
The acquisition of point mutations in the BCR-ABL1
kinase domain (KD) may undermine the efficacy of ima-
tinib, and even second-generation TKIs (dasatinib, nilo-
tinib, bosutinib) maintain a small but definite subset of
resistant mutations [1]. Although dasatinib, nilotinib and
bosutinib have demonstrated good efficacy in patients
resistant to first-line TKI treatment with imatinib, ap-
proximately half of the patients experience a second
relapse [2–4]. Increased expression and functional
reactivation of BCR-ABL1 associated with resistance
[5–7] foster genomic instability and perturbed differ-
entiation, thus increasing the propensity to progress from
chronic phase (CP) to blast crisis (BC) [8–10]. Even in the
TKI era, treatment of BC remains a challenge and patients
who progress have a dismal outcome: hence, preventing
resistance as a mean to prevent disease progression from
CP to BC is a crucial treatment endpoint [11, 12]. The
percentage of patients positive for BCR-ABL1 KD
mutations is approximately 30 % in case of resistance to
first-line TKI treatment and rises up to 50–60 % in case of
resistance to second-line TKI treatment [13]. In patients
already harboring mutations selected by imatinib treat-
ment, acquisition of new mutations conferring resistance
to second-line therapy may give rise to very aggressive
multi-mutated clones (‘compound mutants’) that are very
difficult to counteract [14, 15]. These evidences indicate
that CML patients receiving second-line TKI treatment
are a critical subset: they have a higher risk of disease re-
lapse and progression and not infrequently BCR-ABL1
KD mutations are implicated in therapeutic failure. In this
setting, earlier detection of emerging BCR-ABL1 muta-
tions would therefore be valuable to enable a greater lee-
way in tackling resistance, thus enhancing the efficacy of
salvage therapy.
We have recently set up an assay for next generation
amplicon-based deep sequencing (DS) of the BCR-ABL1
KD and have validated its accuracy, precision, and lin-
earity for detection of any sequence variation down to
1 % [16, 17]. DS might be a reliable and sensitive candi-
date alternative to conventional sequencing, currently
used for routine BCR-ABL1 KD mutation screening
[18, 19]. We thus aimed to assess whether, and in
how many patients receiving second-line TKI therapy,
DS may identify clinically actionable TKI-resistant muta-
tions earlier than conventional sequencing.
Methods
Patients and experimental design
Among the imatinib-resistant CML patients who
switched to second-line TKI therapy and were referred
to our laboratory for routine BCR-ABL1 transcript level
monitoring and KD mutation screening, 51 later ac-
quired dasatinib-(n = 26) or nilotinib-resistant mutations
(n = 25) detected by conventional sequencing at the time
of Failure, after a median of 9 months (range, 3–27
months) of therapy (Table 1). DS reanalysis was per-
formed from the time of failure and mutation detection
by conventional sequencing backwards. A total of 125
peripheral blood samples were studied. For comparison,
15 randomly selected patients with ‘Warning’ response
at various timepoints, that later turned into stable
‘Optimal’ responses without treatment changes, were
also analyzed by DS. No patient with suspected or
confirmed lack of adherence, as well as no patient who had
experienced dose adjustments or temporary discontinuations
Table 1 Patients’ characteristics
Pts, total 51
CP CML 33
AP/BC CML 18
- with baseline IM-resistant mutations 29
- who acquired DAS-resistant mutations 26
T315I 13
F317L/V 10
V299L 3
- who acquired NIL-resistant mutationsa 25
E255K/V 9
F359V/I/C 7
Y253H 6
T315I 4
Median time on 2nd-line therapy, months (range) 9 (3–27)
Abbreviations: CP chronic phase (at the time of second-line TKI therapy start),
AP/BC, accelerated phase or blast crisis (at the time of second-line TKI therapy
start), IM imatinib, DAS dasatinib, NIL nilotinib, the a denotes that one patient
had two mutations
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for toxicity was included in either group. The study was
approved by the Institutional Review Board of the S.
Orsola-Malpighi Hospital (study code 253/2013/O) and
was conducted in accordance with the Declaration of
Helsinki. Written informed consent for participation in this
study was obtained from all the patients. The results of this
study have been presented in abstract form at the 56th an-
nual meeting of the American Society of Hematology
(ASH) in San Francisco (CA) in December 2014.
BCR-ABL1 transcript level monitoring by real time
quantitative polymerase chain reaction (RQ-PCR)
BCR-ABL1/ABL1% transcript levels were assessed by
real time quantitative reverse transcription polymerase
chain reaction (RQ-PCR) as previously described [20]
and were expressed on the International Scale (IS) [21].
Conventional sanger sequencing
Conventional sequencing of the BCR-ABL1 KD, ampli-
fied by nested RT-PCR, was performed according to the
Sanger method on an ABI PRISM 3730 (Applied Biosys-
tems, Foster City, CA) as previously reported [22, 23].
Deep sequencing
The detailed DS protocol has been previously published
[16]. Briefly, four amplicons spanning the BCR-ABL1 KD,
tagged with a 10-base ‘barcode’ sequence (multiplex identi-
fier), were generated by nested reverse transcription poly-
merase chain reaction and pooled in equimolecular ratios.
DS was performed on a GS Junior instrument (Roche) ac-
cording to the manufacturer’s instructions. Sensitivity, ac-
curacy and reproducibility of our DS-based BCR-ABL1
mutation screening assay have already been demonstrated,
as described in [16]. Minimum sequencing depth was
5,000x, ensuring detection of variants down to 1 %. Ampli-
con Variant Analyzer ver2.7 (Roche) was used to align reads
to the reference ABL1 sequence (GenBank accession
no.X16416.1) and to calculate variant frequencies. The pres-
ence of all relevant mutations was also manually verified by
inspection of individual flowgrams at the corresponding po-
sitions, with particular attention to homopolymeric regions
where sequencing errors tend to be more frequent.
Response definitions
BCR-ABL1/ABL1% transcript levels were used to define
whether the patient had an ‘Optimal response’, ‘Warning
Fig. 1 Backtracking dasatinib-resistant mutations by DS. Each line represents a patient and each circle corresponds to a sample. Full and empty
circles indicate samples with mutations detectable or undetectable by DS, respectively. Light grey filling denotes samples in which the mutation
was detectable by DS only. Dark grey filling denotes samples in which the mutation was detectable also by conventional sequencing. For each
type of mutation, numbers in parentheses summarize the number of patients in which the mutation could be backtracked by DS/the total
number of patients who acquired that type of mutation. Percentages indicate mutation relative abundance. ‘F’ means ‘Failure’, ‘W’ means
‘Warning’, ‘O’ means ‘Optimal’ response; ‘B’ means ‘Baseline’
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reponse’ or ‘Failure response’ at the time of first muta-
tion detection by DS, according to the 2013 ELN recom-
mendations [24].
Results
Among the 26 patients who relapsed on dasatinib, 13 had
acquired a T315I mutation, 10 had acquired F317L or V
mutations, and 3 had acquired a V299L mutation (Fig. 1).
DS allowed to backtrack mutations in 11 cases (T315I, n =
2; F317L/V, n = 6; V299L, n = 3). In 2 patients, the muta-
tions were detected at baseline. In the remaining cases, cor-
relation with response at the time mutations were first
detected by DS revealed a ‘Warning’ in 7 cases; a ‘Failure’ in
1 case; an ‘Optimal response’ in 1 case (Fig. 1).
Among the 25 patients who relapsed on nilotinib, 4 had
acquired a T315I mutation, 8 had acquired an E255K or V
mutation, 6 had acquired an F359V or I mutation, 1 had ac-
quired an F359C and an E255K simultaneously, and 6 had
acquired a Y253H mutation (Fig. 2). DS allowed to back-
track mutations in 12 cases (T315I, n = 1; E255K/V, n = 6;
F359V/I, n = 2; Y253H, n = 3). In 3 cases, the mutations
were detected at baseline. In the remaining patients, re-
sponse levels at the time mutations were first detected by
DS were: ‘Warning’ in 6 cases; ‘Failure’ in 3 cases (Fig. 2).
Thus, overall, DS could detect emerging BCR-ABL1
mutants earlier than conventional sequencing (median,
3 months; range, 1–9 months) in 23/51 (45 %) cases.
Median mutation burden at the time of first detection
by DS was 5.5 % (range, 1.5 %–17.5 %).
We next checked if low level mutations can be identi-
fied in cases with ‘Warning’ responses who ultimately
become optimal responders. To address this issue, DS
was also performed, for comparison, in 15 randomly se-
lected patients with ‘Warning’ response at various time-
points, that later turned into stable ‘Optimal’ responses
without treatment changes. Reassuringly, no low-level
TKI-resistant mutations that would have triggered an
unnecessary treatment change were detected by DS.
Finally, we checked how many of the 28 patients in whom
DS failed to detect the emerging mutation(s) in the earlier
sample had a ‘Failure’ or ‘Warning’ response level at that
time – to estimate in how many cases DS would be per-
formed without bringing any advantage over conventional
sequencing. In the dasatinib group, 15 patients had no mu-
tations detectable by DS in the sample immediately before
(most frequently, 3 months before) conventional sequencing
testing. At the corresponding timepoint, 1 patient had a re-
sponse level already classifiable as Failure, 3 patients had a
‘Warning’ response and 11 patients had an ‘Optimal re-
sponse’. In the nilotinib group, patients in whom DS failed
to detect the mutation earlier were 13. Two of them had a
‘Warning’ and 11 had an ‘Optimal response’. So, in our
series, only six cases would have had longitudinal testing by
DS with no earlier detection of the emerging mutation.
Conclusions
Imatinib-resistant CML patients receiving second-line
TKI therapy may develop new mutations leading to a
Fig. 2 Backtracking nilotinib-resistant mutations by DS. See legend to Fig. 1 for explanations and abbreviations
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second relapse. Despite availability of several TKI op-
tions, salvage rates for these patients remain pretty un-
satisfactory [25, 26]. Our results indicate that DS enables
a larger window of detection of emerging BCR-ABL1
KD mutations predicting for an impending relapse. Earl-
ier detection of a mutation known to confer resistance
to the TKI the patient is receiving may offer greater
chances of efficacy for subsequent salvage therapy and
limit the biological consequences of full BCR-ABL1 kin-
ase reactivation.
In order to identify patients with emerging mutations,
when should DS analysis be performed? Regular surveil-
lance of BCR-ABL1 KD sequences by DS in all patients
on second-line therapy, in parallel with RQ-PCR moni-
toring, would not probably be cost-effective. The 2013
ELN treatment recommendations [24] have established
critical checkpoints and definite BCR-ABL1 transcript
level thresholds to define three response categories –
‘Failure’ (the patient should receive a different treatment
to limit the risk of progression and death), ‘Warning’
(more frequent monitoring is needed to permit timely
change in therapy in case of treatment failure) and
‘Optimal’ response (there is no indication for a change
in treatment). In CML patients on second-line TKI ther-
apy, BCR-ABL1 KD mutation analysis by conventional
sequencing is currently recommended at baseline and
the time of ‘Failure’, when it may provide important
information to be included in the therapeutic decision
algorithms [18]. The results of this study provide further
confirmation that DS of the BCR-ABL1 KD at baseline
and at the time of ‘Failure’ would detect mutations in a
greater proportion of patients as compared to conven-
tional sequencing and would better inform therapeutic
choices [27]. More importantly, our findings suggest that
during second-line TKI therapy, DS may identify emer-
ging mutations earlier than conventional sequencing. A
‘Warning’ response may represent, besides ‘Failure’, a
reasonable trigger for the application of DS-based muta-
tion screening. In thirteen cases, low level mutations re-
sistant to the ongoing TKI were retrospectively detected
by DS when response was still at the level of ‘Warning’
and not yet at the level of ‘Failure’. In many patients
‘Warning’ is a transient condition, that may later turn
into ‘Failure’ or, in some cases, into an ‘Optimal’ re-
sponse. To rule out the possibility that, in some cases,
low level mutations resistant to the ongoing TKI may be
a transient finding and may not always correlate with
subsequent treatment failure, we randomly selected 15
patients with ‘Warning’ response that later became
stable optimal responders. DS analysis of the samples
collected at the time of ‘Warning’ in these patients did
not show evidence of low level mutations. This demon-
strates that detection of low burden mutations known to
confer resistance to the TKI the patient is receiving can
reasonably be considered a reliable indication for treat-
ment change in all cases with a ‘Warning’ response.
This study thus provides further evidence of how clin-
ical actionability may be enhanced by routine DS-based
BCR-ABL1 KD mutation screening and comes at a turn-
ing point witnessing a gradual transition from conven-
tional to next-generation sequencing for the diagnostic
assessment of disease (and cancer)-related genes [28]. It
also contributes to build the background for implement-
ing technical and clinical recommendations for CML
monitoring and management.
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